Scholarlink

Purpose <p>To evaluate structural outcomes, including subretinal fluid (SRF) and fibrovascular pigment epithelial detachment (fvPED) volume changes, after switching from aflibercept 2&#xa0;mg to faricimab in Japanese patients with neovascular age-related macular degeneration (nAMD).</p> Study design <p>Retrospective, observational study.</p> Methods <p>Patients with nAMD who were switched from aflibercept 2 mg to faricimab were enrolled. Changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), and the volumes of SRF and fvPED were analyzed using three-dimensional spectral-domain optical coherence tomography data.</p> Results <p>A total of 46 eyes from 46 patients were included. All had been maintained on fixed dosing due to difficulty in extending the injection interval. Patients had received a mean of 25.6 aflibercept 2&#xa0;mg injections, with a mean interval of 7.5&#xa0;weeks for the last three injections. Subsequently, three faricimab injections were given at similar intervals (7.6&#xa0;weeks). BCVA remained unchanged (p = 0.066), while CMT, SRF, and fvPED volumes significantly decreased (p &lt; 0.01). A significant correlation was found between the reductions in SRF and fvPED volumes (p &lt; 0.05).</p> Conclusions <p>Switching to faricimab led to favorable structural outcomes in nAMD patients previously treated with aflibercept 2&#xa0;mg, particularly by reducing SRF and fvPED.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Switching to faricimab alleviates persistent subretinal fluid and pigment epithelial detachment in neovascular age-related macular degeneration

  • 期刊论文

  • 发表日期：

    2025年8月22日

查看全文
  • Yusuke Maehara,
  • Shoji Notomi,
  • Satomi Shiose,
  • Yosuke Fukuda,
  • Kohei Kiyohara,
  • Kumiko Kano,
  • Keijiro Ishikawa,
  • Toshio Hisatomi,
  • Koh-Hei Sonoda

摘要

Purpose

To evaluate structural outcomes, including subretinal fluid (SRF) and fibrovascular pigment epithelial detachment (fvPED) volume changes, after switching from aflibercept 2 mg to faricimab in Japanese patients with neovascular age-related macular degeneration (nAMD).

Study design

Retrospective, observational study.

Methods

Patients with nAMD who were switched from aflibercept 2 mg to faricimab were enrolled. Changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), and the volumes of SRF and fvPED were analyzed using three-dimensional spectral-domain optical coherence tomography data.

Results

A total of 46 eyes from 46 patients were included. All had been maintained on fixed dosing due to difficulty in extending the injection interval. Patients had received a mean of 25.6 aflibercept 2 mg injections, with a mean interval of 7.5 weeks for the last three injections. Subsequently, three faricimab injections were given at similar intervals (7.6 weeks). BCVA remained unchanged (p = 0.066), while CMT, SRF, and fvPED volumes significantly decreased (p < 0.01). A significant correlation was found between the reductions in SRF and fvPED volumes (p < 0.05).

Conclusions

Switching to faricimab led to favorable structural outcomes in nAMD patients previously treated with aflibercept 2 mg, particularly by reducing SRF and fvPED.